2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-124015
    1,1,1-Trifluoro-10(Z)-nonadecen-2-one 177987-23-4 98%
    1,1,1-Trifluoro-10(Z)-nonadecen-2-one (Compound 1) is an inhibitor of oleamide hydrolase.
    1,1,1-Trifluoro-10(Z)-nonadecen-2-one
  • HY-124019
    4,5-DiHDPA lactone 845673-68-9 98%
    4,5-DiHDPA lactone (5), a derivative of docosahexaenoic acid (DHA), is a PPARγ activator.
    4,5-DiHDPA lactone
  • HY-124038
    RX-055 2108098-33-3 98%
    RX-055 is a diazirine-containing photoaffinity probe. RX-055 can be derived from WOBE437. RX-055 can irreversibly block membrane transport of endocannabinoids. RX-055 exerts site-specific anxiolytic effects in brain.
    RX-055
  • HY-124047
    RX 67668 40709-76-0 98%
    RX 67668 is a potent cholinesterase inhibitor with an IC50 of 5 μM for both acetylcholinesterase (AChE) and butyrylcholinesterase. RX 67668 can reverse the neuromuscular blockade induced by D-tubocurarine. RX 67668 is a muscle relaxant used to relieve skeletal muscle fatigue.
    RX 67668
  • HY-124086
    BHQ-O-5HT 1417436-52-2 98%
    BHQ-O-5HT is a light-activated caged 5-HT protected by a BHQ group. When exposed to light at 365 or 740 nm, BHQ-O-5HT releases 5-HT through 1 or 2 photon excitation, respectively. BHQ-O-5HT can be manipulated in space and time to explore the role of 5-HT in regulating mood, appetite, memory, learning, and other cognitive functions.
    BHQ-O-5HT
  • HY-124109
    TRC051384 hydrochloride 1333327-56-2 98%
    TRC051384 hydrochloride is a potent inducer of heat shock protein 70 (HSP70). TRC051384 hydrochloride exhibits protective effects against neuronal trauma via inhibition of necroptosis. TRC051384 hydrochloride can be used for the research of ischemic stroke.
    TRC051384 hydrochloride
  • HY-124110
    TC299423 1975146-56-5 98%
    TC299423 is an orally active, brain-penetrant, selective and potent agonist for α6β2? and α4β2? nicotinic acetylcholine receptors (nAChRs) with anxiolytic and antinociceptive properties. TC299423 acts primarily through α6β2? nAChRs that are implicated in the anxiolytic effects of nicotine. TC299423 elicits reward-related behavior mediated through α6β2? nAChRs in hypersensitive α6L90’S mice. TC299423 elicits dopamine release and dose not suppress nicotine self-administration in rats. TC299423 is proming for rasearch of addiction and Parkinson’s disease.
    TC299423
  • HY-124117
    LY 278584 119193-37-2
    LY 278584 is a potent, highly selective 5-HT3 receptor antagonist with a Ki of 1.62 nM. LY 278584 has no activity on 5-HT1A, 5-HT1B, 5-HT1C, 5-HT1D, or 5-HT2 receptors.
    LY 278584
  • HY-124135
    SB-656104 446020-51-5 98%
    SB-656104 is a potent antagonist of 5-HT7 receptor, with the pKi of 8.70, blocking 5-carboxamidotryptamine (5-CT) stimulated adenylyl cyclase activity.
    SB-656104
  • HY-124152
    3,4-Dephostatin 173043-84-0 98%
    3,4-Dephostatin (Methyl-3,4-dephostatin) is an inhibitor of protein-tyrosine phosphatase (PTPase). 3,4-Dephostatin accelerates nerve growth factor (NGF)-induced neurite formation in PC12h cells. 3,4-Dephostatin sustains the NGF-induced tyrosine phosphorylation of proteins, most prominently that of mitogen-activated protein (MAP) kinase. 3,4-Dephostatin also prolongs epidermal growth factor (EGF)-induced tyrosine phosphorylation and activation of MAP kinase.
    3,4-Dephostatin
  • HY-124160
    JNJ-56022486 2036082-79-6 98%
    JNJ-56022486 is an orally active and potent negative AMPA receptor modulator (Ki=19 nM) selective for?TARP-γ8. JNJ-56022486 is also a TARP-γ8 receptor antagonist, with blood?brain?barrier (BBB) permeability. JNJ-56022486 can be used for research of Epilepsy.
    JNJ-56022486
  • HY-124204
    LY 274614 136109-04-1 98%
    LY 274614 is an orally active, competitive NMDA receptor antagonist. LY 274614 can be used for Neurological Disease study.
    LY 274614
  • HY-124223
    AF-DX 384 methanesulfonate 118290-27-0 98%
    AF-DX 384 (methanesulfonate) is a selective antagonist of M2 and M4 muscarinic acetylcholine receptors (Kis=6.03 and 10 nM, respectively). AF-DX 384 (methanesulfonate) reverses deficits in novel object recognition and passive avoidance in aged rats, as well as in young rats with impairments induced by scopolamine.
    AF-DX 384 methanesulfonate
  • HY-124264
    UBP710 1333111-40-2 98%
    UBP710 is a selective NMDA receptor modulator. UBP710 displays greater activity in potentiating GluN2B-containing receptors than those containing GluN2A.
    UBP710
  • HY-124266
    ML104 1314124-95-2 98%
    ML104 is a SMN1 gene modulator. ML104 is promising for research of neurological diseases.
    ML104
  • HY-124275
    ML389 1622294-25-0 98%
    ML389 is a highly selective vasopressin 1a (V1a) receptor antagonist (IC50=40 nM). ML389 is promising for research of central nervous system disorders such as anxiety, depression, and post-traumatic stress disorder (PTSD).
    ML389
  • HY-124277
    ADM 12 1644134-60-0 98%
    ADM 12 is a highly selective transient receptor potential ankyrin 1 (TRPA1) channel antagonist. ADM 12 blocks nitroglycerin (NTG)-induced trigeminal hyperalgesia in animal models, reducing expression of pain-related genes (c-Fos, TRPA1) and neuropeptides (CGRP, SP). ADM_12 is promising for research of migraine and neuropathic pain.
    ADM 12
  • HY-124296
    2C-TFM hydrochloride 159277-13-1 98%
    2C-TFM hydrochloride is a ,5-dimethoxyphenethylamines compound with a para-trifluoromethyl substitution. 2C-TFM hydrochloride is a potent agonist of the 5-HT receptor subtypes 5-HT2A and 5-HT2C.
    2C-TFM hydrochloride
  • HY-124310
    PDE5-IN-6c 1448419-13-3 98%
    PDE5-IN-6c is a potent and selective phosphodiesterase 5A1 (PDE5A1) inhibitor with the potential to inhibit Alzheimer's disease (AD). PDE5-IN-6c exhibits an excellent in vitro IC50 (0.056 nM), demonstrating its potent inhibitory activity. PDE5-IN-6c has improved water solubility, making it a more attractive drug candidate.
    PDE5-IN-6c
  • HY-124320
    Desmethylene paroxetine hydrochloride 1394861-12-1 98%
    Desmethylene paroxetine hydrochloride is a major urinary metabolite of Paroxetine. Paroxetine is a potent serotonin reuptake inhibitor.
    Desmethylene paroxetine hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity